التفاصيل البيبلوغرافية
| العنوان: |
Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study. |
| المؤلفون: |
Campbell, Bruce CV, Mitchell, Peter J, Churilov, Leonid, Yassi, Nawaf, Kleinig, Timothy J, Yan, Bernard, Thijs, Vincent, Desmond, Patricia M, Parsons, Mark W, Donnan, Geoffrey A, Davis, Stephen M |
| المصدر: |
International Journal of Stroke; Jul2020, Vol. 15 Issue 5, p567-572, 6p |
| مصطلحات موضوعية: |
ENDOVASCULAR surgery, THROMBOLYTIC therapy, CEREBRAL infarction, CEREBRAL hemorrhage, STROKE, INTRACEREBRAL hematoma, TISSUE plasminogen activator |
| الشركة/الكيان: |
NATIONAL Institutes of Health (U.S.) |
| مستخلص: |
Background and hypothesis: Intravenous thrombolysis with tenecteplase is more effective than alteplase in achieving substantial reperfusion at initial angiographic assessment and improves functional outcome. However, the optimal dose of tenecteplase remains uncertain. We hypothesized that 0.40 mg/kg tenecteplase is superior to 0.25 mg/kg tenecteplase in achieving reperfusion at initial angiogram, when administered within 4.5 h of ischemic stroke onset, in patients planned to undergo endovascular therapy. Study design: EXTEND-IA TNK part 2 is an investigator-initiated, phase II, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) study. Eligibility requires a diagnosis of ischemic stroke within 4.5 h of stroke onset, pre-stroke modified Rankin Scale (mRS)≤3 (no upper age limit), absence of contraindications to intravenous thrombolysis, and large vessel occlusion (internal carotid, basilar, or middle cerebral artery) on multimodal CT. Patients are randomized to IV tenecteplase at either 0.40 mg/kg (max 40 mg) or 0.25 mg/kg (max 25 mg) prior to thrombectomy. Study outcomes: The primary outcome measure is reperfusion on the initial catheter angiogram, assessed as modified Treatment In Cerebral Infarction (mTICI) 2b/3, or the absence of retrievable intracranial thrombus. Secondary outcomes include mRS at day 90 and early neurological improvement (reduction in National Institutes of Health Stroke Scale (NIHSS) by ≥8 points or reaching 0–1) at day 3. Safety outcomes are death and symptomatic intracerebral hemorrhage. Trial registration: ClinicalTrials.gov NCT03340493 [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Stroke is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
